A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Epoetin beta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Roche
- 31 Jan 2017 Protocol amendment as there was a change in the primary end-point and also the trial focus.
- 06 Dec 2016 Preliminary results (n=27) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 01 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2018.